New

ThyroKare Tablets

ThyroKare™ (levothyroxine sodium tablets), USP is approved by the FDA (NADA#141-539) for replacement therapy for diminished thyroid function in dogs.

Canine Hypothyroidism: The most common endocrine disorder in dogs, affecting more than 5% of dogs.  While hypothyroidism cannot be cured, daily replacement therapy allows for dogs to live full, normal lives following diagnosis.

Dosage Regimen: The initial dose is 0.1 mg/10 lb (0.01 mg/lb, 0.022 mg/kg) body weight twice daily. To minimize day-to-day variations in serum total thyroxine (tT4) concentrations, owners should consistently administer ThyroKare either with or without food. To maintain serum levothyroxine sodium concentrations over time, therapeutic monitoring should be conducted every four weeks until an adequate maintenance dose is established and then as needed for continued maintenance. Final administered doses calculated for Day 168 in the effectiveness study ranged from 0.04 to 0.18 mg/10 lb (average 0.09 mg/10 lb) or 0.009 to 0.040 mg/kg (average 0.020 mg/kg) twice daily.

Available in multiple sizes.

Complementary Content
${loading}